🇨🇦Canadian I Respirologist🫁| PH-ILD Doctor @uhn| Alumnus @UNB @WesternU @mcmasterU @uniofeastanglia. Founder of https://xitter.cf/t.co/oNgr2twrkQ.
Toronto
Joined September 2019
- Tweets1.2K
- Following790
- Followers580
- Likes2.1K
Pinned Tweet
Our CARE-PF analysis is out in Respirology.
n=4236 fibrotic ILD. Transplant-free survival 91%/72%/57% at 1/3/5 yr (IPF 39%; CTD-ILD 70% at 5 yr).
@UofT @UHN @UofT_DoM
doi.org/10.1002/resp.70305
Tyler Pitre, MD PhD🇨🇦 retweeted
We’re excited to spotlighting past week publications from researchers across the University of Toronto and the Toronto Academic Health Science Network (TAHSN)
#TAHSN #TorontoPainResearch #UTCSP
Tyler Pitre, MD PhD🇨🇦 retweeted
Canada records 60 per cent spike in arrests, detentions of Canadians in United States ctvnews.ca/canada/article/ca…
Tyler Pitre, MD PhD🇨🇦 retweeted
Is JEV a new architecture? It might just be a smallish LLM with a muzzle...#jev #llm #ai
youtube.com/watch?v=UdHV216g…
Is JEV a new architecture? It might just be a smallish LLM with a muzzle...#jev #llm #ai
youtube.com/watch?v=UdHV216g…
Tyler Pitre, MD PhD🇨🇦 retweeted
Which AI should screen 10,000 abstracts?
Chatbots write one word at a time. BERT reads both ways and gives a score you can tune for high recall.
TITAN-SR kept 99.8% of included studies in 22 later Cochrane reviews.
sciencedirect.com/science/ar…
coresr.ai
#SystematicReview #Epi
Pulse-dose steroids for acute exacerbation of IPF: do they actually save lives? 🧵
SAFER just published in AJRCCM, a multicenter randomized trial testing this head-on. Short answer below. 1/5
#IPF #ILD #PulmTwitter
Result: no survival benefit from pulse dosing.
28-day mortality 10.0% vs 14.6% (P=0.55)
90-day mortality 24.5% vs 29.8% (P=0.65)
Wide CIs, and secondary outcomes (ICU, ventilation/ECMO, adverse events) didn't differ either. 4/5
Takeaway: pulse dosing didn't beat a lower-dose regimen, so it's reasonable to question routine pulse use in AE-IPF.
Caveats: open-label, n=100, and not powered to exclude a modest benefit.
doi.org/10.1093/ajrccm/aamag…
#IPF #ILD 5/5
Not all ILA progresses. Can CT AI flag who will?
COPDGene+AGES: MIL-UIP. Score>0.5 → ~13–14%/yr fibrosis↑; death HR~1.6 both cohorts.
Takeaway: automated UIP-like CT may risk-stratify ILA.
Caveat: observational; needs validation.
#ILD #IPF #PulmTwitter
doi.org/10.1093/ajrccm/aamag…
Tyler Pitre, MD PhD🇨🇦 retweeted
coreSR now runs inside Claude and ChatGPT
I connected the coreSR MCP server and gave Claude one sentence: build a search on sildenafil for pulmonary arterial hypertension, run it, and screen it with TITAN at the strictest setting, randomized trials only.
Twelve minutes later, Claude had searched PubMed and Europe PMC, run TITAN across 1,022 unique records, and written a report that reads like a methods section. It also checked the screen against landmark trials. Two were missing. Claude traced the gap to the search strategy, ran a corrected supplement, and recovered both.
That division of labour is the point. Validated engines do the science. Claude does the legwork. You make the final calls.
The full demo runs under three minutes. Connect at coresr.ai/mcp.
#SystematicReview #EvidenceSynthesis #MetaAnalysis #ClaudeAI
Still hunting IPF biomarkers—MMP-1/9 data.
n=128 IPF (74 stable/54 AE)+26 ctrl. MMP-9 ↑ vs ctrl. Stable IPF: +1 µg/L MMP-1 → +20% death HR (CI 2–42%; adj incl FVC).
Promising stratification; single-center until replicated.
doi.org/10.1177/175346662614…
#IPF #ILD #PulmTwitter
Tyler Pitre, MD PhD🇨🇦 retweeted
This just published paper documents the excellent and, compared to alternatives, superior performance of the title and abstract screening tool of our CoreSR package.
pubmed.ncbi.nlm.nih.gov/4276…
coresr.ai/
Adult idiopathic ILD can be surfactant-gene disease—often missed.
SR n=162 (SFTPA/C, ABCA3, NKX2-1): onset 19–79y; SFTPA familial ± lung Ca; NKX2-1 thyroid/neuro; CT indeterminate.
Genetics: family Hx, younger fibrosis, multi-organ clues.
doi.org/10.1080/25310429.202…
#ILD #IPF
Why SLE breeds PAH: BAFF drives a B→T→endothelium axis (Circ Res).
BAFF-Tg mice get SLE+PAH; B cells activate Gzmk+ CD8s → FasL endothelial apoptosis. Belimumab helped in 2 models.
Promising SLE-PAH target—animal data, not a pt RCT
doi.org/10.1161/CIRCRESAHA.1…
#PAH #PH #MedTwitter
PA dilation tempts as a PH screen in lung disease—fibrosis blunts it.
PVDOMICS n=252: PA size tracked mPAP (ρ≈0.5) & PH (OR~4–6). AUC~0.79; weaker in ILD (0.70) vs obstructive (0.87).
Don't call PH from PA size alone in fibrotic ILD.
doi.org/10.1016/j.chest.2026…
#ILD #PH #PulmTwitter
Inhaled treprostinil now has pooled phase 3 FVC numbers in IPF—not just PH-ILD.
TETON-1+2, n=1191. 52-wk FVC -45 vs -162 ml (diff +112, p<0.0001); delayed worsening too.
Clear FVC signal on antifibrotics. Caveat: cough; deaths NS.
doi.org/10.1093/ajrccm/aamag…
#IPF #ILD #PulmTwitter
Myositis-ILD AE: inpatient mortality still high — MDA5 + low CD4+ mark the worst.
n=35 DM/PM-AEILD: death 42.9% (66.7% anti-MDA5+). CD4+ best predictor (AUC 0.933; cut-off 373/µL).
Stratify early. Small retrospective cohort.
doi.org/10.1007/s10067-026-0…
#ILD #MedTwitter #PulmTwitter
Tyler Pitre, MD PhD🇨🇦 retweeted
Our TITAN-SR validation paper is out in Journal of Clinical Epidemiology.
Biomedical BERT ensemble for title/abstract screening — trained on ~20k reviews — beat ASReview and commercial LLM chatbots.
doi.org/10.1016/j.jclinepi.2…
#SystematicReview #EvidenceSynthesis